U.S. Psychiatric & Mental Health Congress

Industry Supported Symposia 2008 Psychiatric Congress
Below is the schedule for the Industry-Supported Symposia.
These symposia are supported by educational grants from pharmaceutical companies. This program is independent, fair-balanced, and conforms to the Essentials of the ACCME and OIG and FDA guidelines.
Note: Syllabi for Industry-Supported Symposia will be handed out on-site prior to each symposium.

Reminder:
Seating is available on a first-come, first-served basis only. Please plan to arrive early to ensure a seat.

Thursday, Oct. 30
7:00-9:00 a.m.
11-0 Managing the Complex Patient with Insomnia and Comorbid Conditions: Rationale for Treatment Selection
Breakfast Symposium – 1.5 Credits Marriott Hall
This program is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
David N. Neubauer, MD
Associate Director, Johns Hopkins Sleep Disorders Center; Assistant Professor of Psychiatry, Johns Hopkins
Karl Doghramji, MD
Professor of Psychiatry, Jefferson Medical College; Director, Sleep Disorders Center, Thomas Jefferson University Hospital
Sonia Ancoli-Israel, PhD Professor of Psychiatry, UCSD
Michael J. Thorpy, MD
Director, Sleep-Wake Disorders Center, Montefiore Medical Center, Bronx; Professor of Neurology, Albert Einstein College of Medicine

9:30-10:45 a.m.
12-0 Differential Diagnosis of Bipolar Disorder Subtypes: Indications for Adjunctive Therapies
Symposium Room 30C
Supported through an educational grant by Janssen, L.P., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Alex Alva, MD
Chief Medical Officer, Pacific Neuropsychiatric Specialists; Medical Director, ATP Clinical Research Group
Michael J. Gitlin, MD
Professor of Clinical Psychiatry, UCLA; Director, Mood Disorders Clinic, UCLA Neuropsychiatric Hospital; Director, Adult Division of Psychiatry, UCLA

13-0 Taking Psychiatry Beyond Mental Health: A Focus on Fibromyalgia
Symposium Room 33
Supported by an educational grant from Eli Lilly and Company.
Don L. Goldenberg, MD
Chief of Rheumatology, Newton-Wellesley Hospital; Professor of Medicine, Tufts University School of Medicine; Director, Arthritis-Fibromyalgia Center of Newton-Wellesley Hospital
Roy A. Kaplan, MD
Assistant Clinical Professor, Department of Medicine, Division of Rheumatology, UCSD

11:00 a.m. – 12:15 p.m.
14-0 Improving Outcomes in the Treatment of Major Depressive Disorder: Augmenting Traditional Therapies with Atypical Antipsychotics
Symposium Room 33
Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Norman Sussman, MD
Professor of Psychiatry, New York University; Associate Dean for Postgraduate Programs, New York University School of Medicine
J. Craig Nelson, MD
Leon J. Epstein Professor of Psychiatry, Director of Geriatric Psychiatry, UCSF

12:30 – 2:30 p.m.
16-0 Schizophrenia vs. Schizoaffective Disorder: Clinical Implications for Therapeutic Decisions
Lunch Symposium – 1.5 Credits Ballroom 20
Supported through an educational grant by Janssen, L.P., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Gustavo Alva, MD
Medical Director, ATP Clinical Research, Costa Mesa, CA
David C. Henderson, MD
Associate Professor of Psychiatry, Harvard; Associate Director of Schizophrenia Program, Massachusetts General Hospital

7:00 – 9:00 p.m.
19-0 Expanding the Armamentarium in the Treatment of Insomnia: Understanding the Pharmacology of Current and Emerging Treatments
Dinner Symposium – 1.5 Credits Marriott Hall
Supported by an educational grant from Somaxon Pharmaceuticals, Inc.
Gary K. Zammit, PhD
Director, Sleep Disorders Institute; Clinical Associate Professor of Psychology in Psychiatry, Columbia University College of Physicians and Surgeons
Thomas Roth, PhD
Director, Sleep Disorders and Research Center, Henry Ford Hospital; Clinical Professor, Department of Psychiatry, University of Michigan; Chief, Sleep Medicine, Henry Ford Hospital
DUSTRY SUPPORTED SYMPOSIA
Friday, Oct. 31
7:00 – 9:00 a.m.
21-0 Understanding the Complexities in the Management of Insomnia and Depression:
Spotlight on Current and Emerging Therapies
Breakfast Symposium – 1.5 Credits Marriott Hall
Supported by an educational grant from sanofi-aventis U.S. Inc.
Charles DeBattista, MD, DMH
Professor of Psychiatry; Director of Depression Research and Psychopharmacology Clinics; Director of Medical Student Education in Psychiatry, Stanford University School of Medicine
Milton K. Erman, MD
Voluntary Clinical Professor, Department of Psychiatry, School of Medicine, UCSD; Chief Medical Officer, Avastra, USA, Irvine, CA; Staff Scientist, Department of Neuropharmacology, The Scripps
Research Institute, La Jolla, CA

9:30 – 10:45 a.m.
22-0 Essential Elements in the Diagnosis and Treatment of Adult ADHD: Pathways to
Optimized Care
Symposium Room 33
Supported by an educational grant from Eli Lilly and Company.
Joel L. Young, MD
Medical Director and Founder, Rochester Center for Behavioral Medicine
Michael A. Schwartz, MD
Clinical Professor of Psychiatry, University of Hawaii

12:30 – 2:30 p.m.
25-0 Navigating the Clinical Conundrum of Major Depressive Disorder
Lunch Symposium – 1.5 Credits Ballroom 20
Supported by an educational grant from Eli Lilly and Company.
Rakesh Jain, MD, MPH
Assistant Clinical Professor of Psychiatry, University of Texas Medical School, Houston; Director, Psychiatric Drug Research, R/D Clinical Research Center, Lake Jackson, TX; 2008 Psychiatric
Congress Teacher of the Year
James W. Jefferson, MD
Distinguished Senior Scientist, Madison Institute of Medicine, Inc.; Director, Healthcare Technology Systems, Inc.; Clinical Professor of Psychiatry, University of Wisconsin

7:15 – 9:15 p.m.
28-0 The Importance of Diagnosis of Bipolar Disorder and Effective Management
Dinner Symposium – 1.5 Credits Marriott Hall
Supported by an educational grant from Eli Lilly and Company.
Caleb Adler, MD
Associate Professor of Clinical Psychiatry and Neuroscience; Co-Director, Division of Bipolar Disorders Research; Assistant Director, Center for Imaging Research, University of Cincinnati
College of Medicine
Terence Ketter, MD
Professor of Psychiatry and Behavioral Sciences; Chief, Bipolar Disorders Clinic, Stanford

Saturday, Nov. 1
7:00 – 9:00 a.m.
31-0 Update on ADHD Therapy: Meeting the Needs of Every Patient
Breakfast Symposium – 1.5 Credits Marriott Hall
Supported by an educational grant from Shire Pharmaceutical Inc.
Birgit Amann, MD
Medical Director, Behavioral Medical Center, Troy, MI
Doris Greenberg, MD
Associate Professor of Pediatrics, Mercer University School of Medicine, Savannah, GA

12:30 – 2:30 p.m.
34-0 Addressing the Chronicity of ADHD Across the Life Span: Implications for Long-Term
Adherence
Lunch Symposium – 1.5 Credits Ballroom 20
This activity is supported by an educational grant from McNeil Pediatrics Division of McNeil-PPC, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Sharon Wigal, PhD
Clinical Professor of Pediatrics, Director of Clinical Trials, UCI Child Development Center
Kenneth Steinhoff, MD
Associate Clinical Professor of Psychiatry and Human Behavior, University of California, Irvine

Sunday, Nov. 2
7:00 – 9:00 a.m.
41-0 Anxiety with Comorbid Depression: The Rule Rather Than the Exception
Breakfast Symposium – 1.5 Credits Ballroom 20
Supported by an educational grant from Forest Research Institute, Inc. a wholly-owned subsidiary of Forest Laboratories Inc.
Joseph A. Lieberman III, MD, MPH

Professor of Family Medicine, Jefferson Medical College, Philadelphia; Associate Editor,

Murray B. Stein, MD
Professor of Psychiatry and Family & Preventive Medicine, UCSD; Director, Anxiety & Traumatic Stress Disorders Program, VA San Diego Healthcare System

Plan Your Schedule with our Educational Track System

AP        =          Addiction Psychiatry
CA        =          Child and Adolescent Psychiatry
CAM    =          Complementary and Alternative Medicine
GP       =          Geriatric Psychiatry
NP        =          Neuropsychiatry
PI         =          Practice Issues, Ethics and Forensic Psychiatry
PD        =          Psychiatric Disorders
PM       =          Psychosomatic Medicine
PT        =          Psychotherapy
RX        =          Psychopharmacology
SC        =          Social and Community Psychiatry
VT        =          Violence and Trauma

Addiction Psychiatry AP
11-2 Introduction to Drug Abuse and Dependency: New Insights from Cocaine to Alcohol
12-1 Globesity: Crisis, Prospects and New Treatments
14-3 New Clinical Research with Psychedelic Drugs
22-2 Pharmacotherapy of Dual-Diagnosis Patients
23-2 Alcohol Withdrawal Syndromes: Pathophysiology and Management
24-4 Club Drugs and Their Psychiatric Manifestations
25-1 Use and Abuse of Prescription of Analgesics
26-3 Practical Management of Comorbid Alcohol Problems in Patients with Bipolar Disorder
33-6 Pharmacologic Treatment of Alcoholism
36-4 Dual Diagnosis

Child and Adolescent Psychiatry CA
13-2 Do Antidepressants Increase the Risk of Suicide?
33-8 Youth Suicide: Who is Most at Risk?
42-5 Self-Injury: Understanding and Working with Teens and Young Adults Who Cut or Burn Themselves

Complementary and Alternative Medicine CAMM
11-1 Treating Returning War Veterans

Geriatric Psychiatry GP
12-3 The Detection of Malingering Using Verbal and Physical "Tells"
14-2 A Biopsychosocial Approach to Pathological Gambling
17-1 The Neurobiology of Empathy
17-3 The Ultimate Personal and Professional Challenge: How to Improve Comfort and Competence with Medical Decision-Making Near the End-of-Life
24-5 Psychiatry's Role in Internet Child Pornography Cases
26-8 Depression and Apathy Associated with Dementia
32-7 Depression vs. Dementia: An Evolving Enigma in the Elderly
34-4 Recognition and Management of Depression in the Older Patient
36-3 Late Life Care: Promise or Peril
41-3 Antipsychotics and the Elderly
43-4 Anxiety in the Elderly

Neuropsychiatry NP
11-3 Neurologic Emergencies
12-2 Falls, Faints, and Fatigue: Evaluation and Treatment of Autonomic Dysfunction
12-3 The Detection of Malingering Using Verbal and Physical "Tells"
16-3 Systems Neuropsychiatry, Part 1: The Decade of the Mind
17-8 Systems Neuropsychiatry, Part 2: The Decade of the Mind and the Future of Clinical Psychiatry
21-3 Neuropsychiatric Masquerades: Medical and Neurologic Disorders That Present with Psychiatric Symptoms
23-1 Happiness: New Insights from Social Psychology and Neuroscience
24-3 A 'Hands On' Workshop for Diagnosing Fibromyalgia in Your Busy Practice
24-6 Aggression: From Evolutionary Psychology to Neurobiology to Practical Treatment
26-8 Depression and Apathy Associated with Dementia
31-4 No Lobe Unprobed: Mastering the Mental Status Exam
32-7 Depression vs. Dementia: An Evolving Enigma in the Elderly
33-4 What's New: Fibromyalgia Syndrome
36-5 Andropause: What Every Man Should Know
42-3 Headache Management 2008
43-2 Neuropathic Pain: Diagnosis and New Treatment Options

Practice Issues, Ethics and Forensic Psychiatry PI
11-0 Managing the Complex Patient with Insomnia and Comorbid Conditions: Rationale for Treatment Selection
13-3 A Busy Clinician’s ‘Treasure Chest’: Creating a Tool Box Filled with Screeners and Rating Instruments to Improve Patient Outcomes
14-2 A Biopsychosocial Approach to Pathological Gambling
15-1 Dealing with Career Frustration: How to Create Job Fulfillment, Free Up Personal Time and Maximize Revenue
15-3 Ooh, Baby, Baby: Adolescents, Sex and the Media
16-1 TV or Not TV: Fat is the Question—Do the Media Cause Obesity and Eating Disorders?
16-4 Young Clinicians Forum
17-2 Workshop: Wellness and Recovery in Traditional Psychiatric Settings: The View From a Long-Term Hospital
17-3 The Ultimate Personal and Professional Challenge: How to Improve Comfort and Competence with Medical Decision-Making Near the End-of-Life
21-1 Practice Management Series 1A: Workflow for Enhanced Productivity
22-1 Practice Management Series 1B: Marketing in Private Practice: Smart Tips Inside and Outside the Psychiatric Office
22-3 Risk Management: What Is It?
24-1 Practice Management Series 1C: Getting Paid: Coding, Contracting and Negotiating
24-7 Tales From the Clinic: Recognizing the Humanity Behind the Patient
25-4 Young Clinicians Forum
26-1 A Busy Clinician’s ‘Treasure Chest’: Creating a Tool Box Filled with Screeners and Rating Instruments to Improve Patient Outcomes
26-2 The Right to Suicide
32-1 Practice Management Series 2A: Workflow for Enhanced Productivity
32-2 Suicide After Familicide, Uxoricide and Mass Murder
32-5 Common Therapeutic Mistakes (and How to Avoid Them!)
33-1 Practice Management Series 2B: Marketing in Private Practice: Smart Tips Inside and Outside the Psychiatric Office
33-5 The Public Psychiatrist: Using Media to Build Trust in Mental Health Care
34-1 Practice Management Series 2C: Getting Paid: Coding, Contracting, and Negotiating
34-2 The Quest for Happiness: Unstalling Stalled Treatment
34-5 Nurses’ Forum
36-1 Innovative Interviewing Techniques for Improving Medication Adherence
36-2 No End to War: The New Wave of PTSD and How News Media Can Influence Outcomes

Psychiatric Disorders PD D
12-0 Differential Diagnosis of Bipolar Disorder Subtypes: Indications for Adjunctive Therapies
12-1 Globesity: Crisis, Prospects and New Treatments
13-0 Taking Psychiatry Beyond Mental Health: A Focus on Fibromyalgia
13-2 Do Antidepressants Increase the Risk of Suicide?
14-0 Improving Outcomes in the Treatment of Major Depressive Disorder: Augmenting Traditional Therapies with Atypical Antipsychotics
15-2 Cognitive Therapy for Depression: Where It Began—An Update
16-0 Schizophrenia vs. Schizoaffective Disorder: Clinical Implications for Therapeutic Decisions
17-2 Workshop: Wellness and Recovery in Traditional Psychiatric Settings: The View From a Long-Term Hospital
17-7 Cognitive Therapy to Aid Adjustment to Cancer: Where It’s Going—A Preview
21-0 Understanding the Complexities in the Management of Insomnia and Depression: Spotlight on Current and Emerging Therapies
21-2 Returning Veterans and Exposure to Depleted Uranium: An Update
22-0 Essential Elements in the Diagnosis and Treatment of Adult ADHD: Pathways to Optimized Care
23-3 Dying for a Drink or Drug: Suicide and Addictions
24-6 Aggression: From Evolutionary Psychology to Neurobiology to Practical Treatment
24-8 Relationship Between Mental Disorders and Pain
26-3 Practical Management of Comorbid Alcohol Problems in Patients with Bipolar Disorder
26-7 HIV and Mood Disorder Prevalence: An Update
26-8 Depression and Apathy Associated with Dementia
28-0 The Importance of Diagnosis of Bipolar Disorder and Effective Management
31-0 Update on ADHD Therapy: Meeting the Needs of Every Patient
32-3 Hunger for Health: The Successful Treatment of Bulimia
32-4 Pharmacotherapy of Bereavement-Related Depression
32-7 Depression vs. Dementia: An Evolving Enigma in the Elderly
33-8 Youth Suicide: Who is Most at Risk?
34-0 Addressing the Chronicity of ADHD Across the Life Span: Implications for Long-
Term Adherence
36-3 Late Life Care: Promise or Peril
36-4 Dual Diagnosis
36-6 Generalized Anxiety Disorder (GAD): Symptoms, Causes and Treatment
41-0 Anxiety with Comorbid Depression: The Rule Rather Than the Exception
41-1 A Futuristic View of the Treatment of Schizophrenia and Alzheimer’s
Disease: Lessons from Early Drug Development
41-2 Psychopharmacology During Pregnancy and Postpartum
42-2 Nurturing the Pregnant Brain: Preventing Postpartum Mood and Anxiety Disorders
43-4 Anxiety in the Elderly

Psychopharmacology RX
12-1 Globesity: Crisis, Prospects and New Treatments
13-0 Taking Psychiatry Beyond Mental Health: A Focus on Fibromyalgia
13-1 Placebo Response in Psychiatric Illness
14-0 Improving Outcomes in the Treatment of Major Depressive Disorder: Augmenting Traditional Therapies with Atypical Antipsychotics
14-1 Libby Zion’s Lesson: Serotonin Syndrome and P450 Drug Interactions
16-0 Schizophrenia vs. Schizoaffective Disorder: Clinical Implications for Therapeutic Decisions
16-2 Drug-Induced Movement Disorders
17-4 Neuroleptic Malignant Syndrome
17-5 Should Side Effects Be the Determining Factor in Choosing an Antipsychotic?
17-6 Psycho-Proctology: The Bottom Line
19-0 Expanding the Armamentarium in the Treatment of Insomnia: Understanding the Pharmacology of Current and Emerging Treatments
22-2 Pharmacotherapy of Dual-Diagnosis Patients
25-0 Navigating the Clinical Conundrum of Major Depressive Disorder
25-3 Current Hot Topics in CNS Drug Development
26-5 Expanding Indications for Psychotropics—Science or Marketing?
28-0 The Importance of Diagnosis of Bipolar Disorder and Effective Management
31-2 Psychoanalysis: What Is Its Role in the 21st Century?
32-4 Pharmacotherapy of Bereavement-Related Depression
33-3 Pharmacotherapy of Complicated Grief
33-6 Pharmacologic Treatment of Alcoholism
34-4 Recognition and Management of Depression in the Older Patient
36-1 Innovative Interviewing Techniques for Improving Medication Adherence
41-0 Anxiety with Comorbid Depression: The Rule Rather Than the Exception
41-1 A Futuristic View of the Treatment of Schizophrenia and Alzheimer’s Disease: Lessons from Early Drug Development
41-3 Antipsychotics and the Elderly
42-2 Nurturing the Pregnant Brain: Preventing Postpartum Mood and Anxiety Disorders

Psychosomatic Medicine PM
24-8 Relationship Between Mental Disorders and Pain
25-0 Navigating the Clinical Conundrum of Major Depressive Disorder
34-3 Collaboration with Primary Care Physicians in Pain Patients
42-6 Feeling Unreal: Assessing Depersonalization Disorder
43-3 Feeling Unreal: Is it for Real? Treatment of Depersonalization Disorder

Psychotherapy PT
11-0 Managing the Complex Patient with Insomnia and Comorbid Conditions: Rationale for Treatment Selection
15-2 Cognitive Therapy for Depression: Where It Began—An Update
16-1 TV or Not TV: Fat is the Question—Do the Media Cause Obesity and Eating Disorders?
17-7 Cognitive Therapy to Aid Adjustment to Cancer: Where It’s Going—A Preview
22-0 Essential Elements in the Diagnosis and Treatment of Adult ADHD: Pathways to Optimized Care
31-0 Update on ADHD Therapy: Meeting the Needs of Every Patient
31-2 Psychoanalysis: What Is Its Role in the 21st Century?
31-3 An Integrative Approach to Marriage Therapy
32-8 Interpersonal Psychotherapy: Women’s Health
33-2 The Seven Keys to Successful Cotreatment
34-0 Addressing the Chronicity of ADHD Across the Life Span: Implications for Long-Term Adherence
36-6 Generalized Anxiety Disorder (GAD): Symptoms, Causes and Treatment
42-1 The Delicate Art of Eliciting Suicidal Ideation and Other Sensitive Material: Part 1
42-5 Self-Injury: Understanding and Working with Teens and Young Adults Who Cut or Burn Themselves
42-6 Feeling Unreal: Assessing Depersonalization Disorder
43-1 The Delicate Art of Eliciting Suicidal Ideation and Other Sensitive Material: Part 2
43-3 Feeling Unreal: Is it for Real? Treatment of Depersonalization Disorder

Social and Community Psychiatry SC
21-2 Returning Veterans and Exposure to Depleted Uranium: An Update
23-1 Happiness: New Insights from Social Psychology and Neuroscience
24-2 Mental Health Reform in Africa and Asia: Case Studies in Local to Global Policy and Practice
25-2 Infidelity I: Basic Background Concepts
26-4 Infidelity II: Clinical Interventions
26-6 Halloween, Holidays and Mental Health
32-8 Interpersonal Psychotherapy: Women’s Health
33-5 The Public Psychiatrist: Using Media to Build Trust in Mental Health Care
36-2 No End to War: The New Wave of PTSD and How News Media can Influence Outcomes

Violence and Trauma VT T
11-1 Treating Returning War Veterans
32-2 Suicide After Familicide, Uxoricide and Mass Murder

Educational Session Descriptions
Thursday, Oct. 30
7:00-9:00 a.m.
11-0 Managing the Complex Patient with Insomnia and Comorbid Conditions:
Rationale for Treatment Selection PI PT
Breakfast Symposium • 1.5 credits
Marriott Hall
This program is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
By participating in this activity, attendees will be able to: 1)Describe the prevalence of comorbid conditions associated with insomnia and the importance of identifying and managing insomnia as a comorbid condition rather than a secondary condition; 2) Investigate the role of risk/benefit analysis in the selection of insomnia pharmacotherapy; and 3) Evaluate current and emerging data relevant to the care of patients with chronic insomnia.

8:00-9:15 a.m.
11-1 Treating Returning War Veterans CAM VT
Room 30A
Universities, private firms and the federal government are spending millions of dollars creating and testing computerized virtual reality to help ease the psychiatric disorders in combat personnel. By participating in this activity, attendees will be able to: 1) Describe the reasons for the relatively scant literature on combat veterans; 2) Outline special considerations
for treatment of combat veterans (via case studies); and 3) Evaluate preliminary data on biomarkers that can be used to predict outcome of psychotherapy.

11-2 Introduction to Drug Abuse and Dependency: New Insights from Cocaine to Alcohol AP
Room 29A
Research is improving our understanding of drug dependency and abuse in all areas: from diagnosis to treatment to maintenance of abstinence. By participating in this activity,
attendees will be able to: 1) Discuss the latest research findings on abuse and dependency of many substances; 2) Identify areas for future research; and 3) Discuss how to apply research to
clinical practice.

11-3 Neurologic Emergencies NP
Room 31A
Through the use of case studies, this lecture will update knowledge in recognition and management of acute neurologic disorders that may first present to the psychiatrist. By
participating in this activity, attendees will be able to: 1) Identify status epilepticus, coma and subarachnoid hemorrhage; 2) Describe pupillomotor function in CNIII Palsies and prognosis;
and 3) Incorporate cost-effective testing and apply principles to treatment and rehabilitation.

9:30-10:45 a.m.
12-0 Differential Diagnosis of Bipolar Disorder Subtypes: Indications for
Adjunctive Therapies PD
Symposium Room 30C
Supported through an educational grant by Janssen, L.P.,

administered by Ortho-McNeil Janssen Scientific Affairs, LLC
By participating in this activity, attendees will be able to: 1) Outline the importance of proper diagnosis of bipolar disorder and the potential ramifications of misdiagnosed BD; 2) Review
the mechanisms of action of antipsychotics and the rationale for polypharmacy in BD; and
3) Compare and contrast the efficacy and safety of current and emerging treatment options
used in the acute and long term management of BD.

12-1 Globesity: Crisis, Prospects and New TreatmentsAP PD RX AP PD RX
Room 29A

The rising epidemic of obesity is called “globesity” by WHO and is affecting millions of people worldwide. By participating in this activity, attendees will be able to: 1) List major illnesses associated with obesity; 2) Discuss the epidemiology of obesity and overweight; and 3) Assess current theories, current treatment approaches—including minimally invasive surgery—and experimental approaches that have resulted from tests concluding that highly palatable, erotic and exotic foods act in the brain as a drug of abuse.

12-2 Falls, Faints, and Fatigue: Evaluation and Treatment of Autonomic Dysfunction NP
Room 31A
This course provides an overview of a clinical approach to diagnosis, evaluation and management of Falls, Faints, and Fatigue: Evaluation and Treatment of Autonomic Dysfunction.
By participating in this activity, attendees will be able to: 1) Discuss the clinical cases of orthostatic hypotension, orthostatic intolerance, autonomic neuropathies and disorders
of sweating; 2) Discuss patient care by highlighting the ways by which the clinician can provide useful consultations and effectively manage patients suffering from Falls, Faints, and
Fatigue: Evaluation and Treatment of Autonomic Dysfunction; and 3) Formulate a differential diagnosis and offer a treatment plan for patients with common and less common varieties of
autonomic dysfunction.

12-3 The Detection of Malingering Using Verbal and Physical “Tells” GP NP GP NP
Room 30A
Psychiatrists have heretofore mostly relied on forensic literature and psychological tests such as the MMPI to detect malingering. However, a recent explosion in poker and law-enforcement literature on verbal and physical “tells” has expanded the possibilities for the evaluation of deception. Mental health professionals should be familiar with this new approach. By participating in this activity, attendees will be able to: 1) Review the psychiatric approach to the detection of malingering; 2) Explore the emergence of poker and law enforcement literature in the area of verbal and physical “tells”; and 3) Examine how these “tells” might be used by the clinical psychiatrist to improve patient care.

13-0 Taking Psychiatry Beyond Mental Health: A Focus on Fibromyalgia PD RX
Symposium Room 33
Supported by an educational grant from Eli Lilly and Company.
Patients with fibromyalgia continuously suffer from chronic widespread pain, major depression, fatigue and sleep disorders. Due to the presence of generalized symptoms and lack of a specific objective diagnostic test, fibromyalgia can be difficult to diagnose. In addition to common symptoms, patients with fibromyalgia are likely to experience comorbid conditions and psychiatric disorders. Recent findings have led to new and emerging therapies that are able to alleviate
multiple symptoms safely and effectively. By participating in this activity, attendees will be able to: 1) Understand the pathophysiology of fibromyalgia; 2) Identify challenges in the
diagnosis of fibromyalgia including overlapping symptomatology and comorbid conditions; and
3) Evaluate the efficacy and safety of nonpharmacologic and pharmacologic therapies for the management of fibromyalgia.

13-1 Placebo Response in Psychiatric Illness RX
Room 29C
Results from studies of psychotropic medications often show a placebo response almost equal to active medication. Does this mean medications used to treat mental illness are no more effective than placebo? By participating in this activity, attendees will be able to: 1) Analyze typical medication study designs; 2) Assess the results of recent psychotropic medications studies; and 3) Discuss the place “placebo” has in medical treatment.

13-2 Do Antidepressants Increase the Risk of Suicide? CA PD CA PD
Room 28A
About 5% of adolescents suffer from depression and suicide is the third leading cause of death in the US for ages 10 through 24. The introduction of a safer generation of antidepressants (e.g., SSRIs; SNRIs) led to their widespread use and correlated with a decrease in the suicide rate in this age group. More recently, however, the FDA mandated a boxed warning for all antidepressants due to concerns about an increased risk for “suicidality” with these agents when compared to placebo in controlled trials. The results of this action on drug treatment of depression and the impact on suicide rates will be discussed. By participating in this activity, attendees will be able to: 1) Analyze the data from the FDA and independent investigators’
reviews regarding this risk of suicidality; 2) Describe the possible differential impact of these agents on suicide across the life cycle; and 3) Formulate an appropriate strategy to treat depression and suicidality in younger age groups.

13-3 A Busy Clinician’s ‘Treasure Chest’: Creating a Tool Box Filled with
Screeners and Rating Instruments to Improve Patient Outcomes PI I
Room 28C
Both psychiatric and nonpsychiatric clinicians tend to underutilize screeners and rating instruments in their busy practices. This is an error worth rectifying expeditiously for the
following reasons: use of screeners and rating instruments can actually improve outcomes, it can be very time efficient and many quality tools are available for no charge. This workshop
will show videos of a few clinical scenarios and discuss what tools might have been appropriate to use. Copies of noncopyrighted screeners and rating instruments, appropriate for both psychiatric and nonpsychiatric settings, will be made available to participants. A toolkit filled of screeners and rating instruments will be brought to the workshop to show participants how they can create one for their own use. By participating in this activity, attendees will be able to:
1) Recognize the many noncopyrighted tools available for clinician use covering a range of psychiatric disorders; 2) Define these tools that are very time efficient and improve diagnostic yield; and 3) Describe how to choose the right tool and how to score them.

11:00 a.m.-12:15 p.m.
14-0 Improving Outcomes in the Treatment of Major Depressive Disorder: Augmenting
Traditional Therapies with Atypical Antipsychotics PD RX PD RX
Room 33
Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Major depressive disorder is associated with substantial morbidity, mortality, family burden and health care costs. Recent studies including the STAR*D trial have shown that the majority of patients fail to achieve remission with standard initial therapies. Since no single treatment is effective, subsequent interventions are often needed. By understanding the strategies necessary to improve overall response rates, clinicians will be better able to reduce relapse rates and
improve overall outcomes in patients suffering from depression. By participating in this activity, attendees will be able to 1) Outline the current remission rates with first-line therapies and
identify the goals of therapy in the treatment of MDD; 2) Explain when augmentation strategies should be considered in the treatment of MDD and the pharmacologic basis for treatment options; and 3) Compare and contrast the efficacy and safety of atypical antipsychotics when used as augmentation in the treatment of depression.

14-1 Libby Zion’s Lesson: Serotonin Syndrome and P450 Drug Interactions RX X
Room 31A
This course discusses common drug-drug interactions that physicians face in clinical practice. By participating in this activity, attendees will be able to: 1) Identify the most common mechanisms underlying drug-drug interactions; 2) Describe common drug-drug interactions affecting U.S. Food and Drug Administration–approved agents and detail dose adjustments where appropriate; and 3) Discuss the recommendations on how to resolve contraindications or manage interactions.

14-2 A Biopsychosocial Approach to Pathological Gambling GP PI
Room 30A
The current poker “craze” has led to an increase in the incidence of pathological gambling in multiple epidemiologic sectors of the United States. As such, it is more important than ever for mental health experts to be familiar with the diagnosis, evaluation and treatment of this disorder. By participating in this activity, attendees will be able to: 1) Examine the diagnostic
criteria for pathological gambling; 2) Explore the manifestations of pathological gambling related to both “online” and “live” play; and 3) Evaluate the treatment modalities that may be
employed to assist pathological gamblers.

14-3 New Clinical Research with Psychedelic Drugs AP
Room 29C
After a 40-year research hiatus, psychedelic drugs are once again being examined for their clinical usefulness. Recent careful systematic studies show that these and related compounds have promise for the treatment of depression, and preliminary studies suggest their usefulness in the management of terminal illness, OCD, cluster headache and addictions. By participating in this activity, attendees will be able to: 1) Describe the effects of ketamine in depression;
2) Discuss the evidence for the usefulness of psychedelic drugs in the treatment of alcohol dependence; and 3) Explain the mechanisms by which psychedelic drugs may alleviate the suffering of the terminally ill.

15-1 Dealing with Career Frustration: How to Create Job Fulfillment, Free Up Personal
Time and Maximize Revenue PI
Room 29A
The practice of psychiatry can be a source of both great satisfaction and great stress. By participating in this activity, attendees will be able to: 1) Identify professional goals; 2) Recognize the steps for recovering from burnout and avoiding burnout altogether; and 3) Discuss the management of career specific stressors, and how they can achieve balance between
their personal and professional lives to maximize satisfaction.

15-2 Cognitive Therapy for Depression: Where It Began—An Update PD PT PD PT
Room 28A
This course will trace the evolution of the cognitive therapy model for treating depression. It will define and describe cognitive therapy, then illustrate a typical session and present several successfully treated cases. By participating in this activity, attendees will be able to: 1) Explain how cognitive therapy has become one of psychotherapy’s major treatment modalities for depression; 2) Describe the range and creativity encompassed by the cognitive model for the clinician treating depression; and 3) Apply a cognitive framework for depression to a group of patients, and also to a clinician’s own patients.

15-3 Ooh, Baby, Baby: Adolescents, Sex and the Media PI
Room 28C
Do the media merely “reflect” the real world–as Hollywood and network executives would have us believe–or do they cause real-life problems as well? Do the media contribute to early sexual intercourse? Could the media increase teens’ use of contraception? This talk will try to illuminate what we know about the impact of the media on adolescents, what we don’t know, and what we need to do to find out. Several suggestions for parents and for schools will be presented. By participating in this activity, attendees will be able to: 1) Describe the nature of current television programming for adolescents; 2) Discuss the impact of television programming on children and teens and how such effects were determined by research; and 3) Identify how the adverse effects of TV and other media can be mediated by parents and by school media literacy program.

12:30-2:30 p.m.
16-0 Schizophrenia vs. Schizoaffective Disorder: Clinical Implications for
Therapeutic Decisions PD RX PD RX
Lunch Symposium • 1.5 credits
Ballroom 20
Supported through an educational grant by Janssen, L.P., administered by Ortho-McNeil Janssen Scientific Affairs, LLC
By participating in this activity, attendees will be able to: 1) Explain the differential diagnosis of schizophrenia versus schizoaffective disorder; 2) Individualize treatment plans for schizophrenia versus schizoaffective disorder; and 3) Outline the factors that contribute to non adherence and the impact of non adherence on healthcare outcomes in schizophrenia and schizoaffective disorder.

1:15-2:30 p.m.
16-1 TV or Not TV: Fat Is the Question–Do the Media Cause Obesity and Eating Disorders? PI PT
Room 28C
Is there a link between TV and obesity? Do the media have an impact on adolescent eating disorders? The answer lies partially in some voluminous and difficult media research and partially in the realm of common sense. This talk will explore the three related topics of obesity, eating disorders, and body image, along with videotaped clips to illustrate the problems and some of the solutions. Several suggestions for parents and for schools will be presented. By participating in this activity, attendees will be able to: 1) Describe the nature of current television programming for adolescents (topic areas=body self-image, obesity, eating disorders); 2) Discuss the impact of television programming on children and teens and how such effects were determined by research; and 3) Identify how the adverse effects of TV and other media can be mediated by parents and by school media literacy programs.

16-2 Drug-Induced Movement Disorders RX
Room 31A
Drug-induced movement disorders present a unique challenge for neuroscience practitioners. By participating in this activity, attendees will be able to: 1) Discuss the pathophysiology of drug-induced movement disorders; 2) Recognize the classes of drugs that are known to affect central dopaminergic systems and cause drug-induced movement disorders; and 3) Identify the risk factors, management and prognosis for drug-induced movement disorders.

16-3 Systems Neuropsychiatry, Part 1: The Decade of the Mind NP
Room 29C
Ten prominent neuroscientists, one of them a psychiatrist, proposed in a Fall 2007 letter in Science magazine that the years 2010-2020 be devoted to a paradigm-shifting, major national research initiative: “The Decade of the Mind.” Others have asked for a coordinated international effort. Beginning with the stunning assertion that “A deep scientific understanding of how the mind perceives, thinks, and acts is within our grasp,” the Science proposal spans disparate fields such as cognitive science, medicine, neuroscience, psychology, mathematics, engineering, and computer science, with additional important insights from systems biology, cultural anthropology, social science, robotics and automation technology. For psychiatry, the implications are vast and hardly tapped, and they will be introduced in this two part seminar. Part 1 will focus upon the foundational base that cognitive neuropsychiatry affords clinical practice in the upcoming “Decade of the Mind.” By participating in this activity, attendees will be able to: 1) Describe the proposed 2010 – 2020 “Decade of the Mind,” a decade that will radically transform the way in which we promote mental health and understand and treat psychiatric disorders; 2) Identify the four pivotal, intertwined domains to be focused upon in the undertaking (healing and protecting, understanding, enriching and modeling the mind); and 3) Incorporate this knowledge into daily practice.
2008 Psychiatric Congress
1:15-3:15 p.m.
16-4 Young Clinicians Forum PI
2.0 Credits
Room 28E
I’m a doctor – now what do I do? Medical schools provide quality education, but do not offer real life practical information on the many scenarios facing young clinicians today. This interactive roundtable discussion offers the opportunity to gain insight from seasoned professionals on a variety of pertinent issues. By participating in this activity, attendees will 1) Demonstrate a deeper understanding of the business and practice aspects of medicine through sharing and networking with peers; 2) Discuss and explore practice issues affecting young clinicians; and 3) Discover how to equip themselves to respond effectively and prepare for the future as health care professionals.

2:45-4:00 p.m.
17-1 The Neurobiology of Empathy GP P
Room 30C
The activation of mirror neurons has been shown to mediate complex human behaviors, from active empathy to the perception of other people’s motivational states (Theory of Mind). By participating in this activity, attendees will be able to: 1) Explore the biology of this fascinating group of neurons; 2) Speculate how such knowledge potentially provides an impact to modern psychiatry; and 3) Discuss the theories that integrate behavioral, affective and cognitive elements of empathy.

17-2 Workshop: Wellness and Recovery in Traditional Psychiatric Settings: The
View from a Long-Term Hospital PI PD PI PD
Room 30A
Wellness and Recovery is an emerging concept that may be perceived as challenging some traditional psychiatric practices. During the past 5 years, we have worked to introduce Wellness
and Recovery principles into a highly traditional long term psychiatric hospital as part of a multidisciplinary University-State Hospital affiliation. This has included psychiatry, nursing, psychiatric rehabilitation, and social work and the introduction of programs such as Illness Management and Recovery, Nurse Directed Care, Therapeutic Communication, a discharge-oriented Therapeutic Alliance group model, and community interface initiatives. The proposed workshop will explore issues and challenges relating to integrating these themes and approaches as well as implications for general psychiatric practice. By participating in this activity, attendees will be able to: 1) List principles and practices associated with Recovery and Wellness as it relates to psychiatric settings 2) Identify methods for using Wellness and Recovery principles
to enhance the therapeutic alliance and efficacy of treatment, including for persons perceived as “resistant” to treatment and to community living; and 3) Describe methods to enhance collaborative relationships with community residential and clinical support providers.

17-3 The Ultimate Personal and Professional Challenge: How to Improve Comfort and
Competence with Medical Decision-Making Near the End-of-Life GP PI
Room 29A
The end of a person’s life can be one of the most important times of that life. The purpose of this course is to equip physicians with knowledge, skills and attitudes that can be tailored to their unique practice setting. By participating in this activity, attendees will be able to: 1) Describe how the changing demographics of aging will impact the healthcare system; 2) Identify the factors measured in determining whether patients are competent to make decisions regarding their medical care; and 3) Describe ways to discuss care options with families and caregivers.

17-4 Neuroleptic Malignant Syndrome RX
Room 31A
This course provides information on NMS diagnosis and treatment based on the most current research. By participating in this activity, attendees will be able to: 1) Recognize the clinical signs of NMS associated with typical and atypical antipsychotics to help determine a diagnosis;
2) Identify related conditions and risk factors associated with the development of NMS;
3) Discuss the differential diagnosis and strategies for the treatment of NMS.

17-5 Should Side Effects Be the Determining Factor in Choosing an Antipsychotic? RX Room 28C
The choice of the right atypical antipsychotic for an individual patient can be a daunting challenge to most physicians. By participating in this activity, attendees will be able to: 1) Discuss side effects of first-and-second generation antipsychotics; 2) Identify side effect profiles among second generation antipsychotics; and 3) Develop a treatment strategy that includes risk/benefit ratio as a determining factor in choice of antipsychotic.

17-6 Psycho-Proctology: The Bottom Line RX
Room 33
Constipation is a major side effect of many of the pharmacological agents used in psychiatry and is believed to be an anticholinergic side effect. By participating in this activity, attendees will be able to: 1) Discuss the consequences of undertreated, or unrecognized, severe psychiatric drug associated constipation progressing to fatal bowel obstruction; 2) Recognize the possibilities such as altered sensitivity to pain and difficulty expressing the pain associated with certain psychiatric disorders (e.g., constipation in schizophrenia patients); and 3) Identify guidelines to recognize the symptoms of constipation in psychiatric patients.

17-7 Cognitive Therapy to Aid Adjustment to Cancer: Where It’s Going— A Preview PD PT
Room 28A
This course will consider different formats for a psychiatrist working in an oncology setting, leading to a focus on the role of a mental health clinician in a private oncology practice. Cognitive therapy approaches to problems adjusting to cancer at its various stages will be discussed. By participating in this activity, attendees will be able to: 1) Identify ways to succeed in mental health work in a medical setting alongside oncologists and their staff; 2) Describe the trajectories involved in cancer, and the patient’s needs at each stage; and 3) Express the suitability of cognitive therapy as a framework for helping a patient deal with issues raised by a diagnosis of cancer.

17-8 Systems Neuropsychiatry, Part 2: The Decade of the Mind and the Future of Clinical Psychiatry NP
Room 29C
The treatment of psychiatric disorders and the promotion and protection of mental health are pivotal to the upcoming 2010 – 2020 “Decade of the Mind” (see Systems Neuropsychiatry, Part
1: The Decade of the Mind), as are the notions of understanding, enriching, and modeling the mind. Consequences for clinical psychiatry of the ‘Decade of the Mind” are elaborated upon in the second of this two part seminar. By participating in this activity, attendees will be able to:
1) Describe how cognitive neuropsychiatry becomes the framework for psychiatry in a “Decade of the Mind”; 2) Identify the challenges and opportunities that this new paradigm offers psychiatric diagnosis, treatment planning, treatment and prevention; and 3) Express how “learning” a transdisciplinary approach, which characterizes best practice in the Decade of the Mind, is beneficial to practice.

3:45-6:45 p.m.
Exhibit Hall

7:00-9:00 p.m.
19-0 Expanding the Armamentarium in the Treatment of Insomnia: Understanding the Pharmacology of Current and Emerging Treatments RX
Dinner Symposium • 1.5 credits
Marriott Hall
Supported by an educational grant from Somaxon Pharmaceuticals, Inc.
By participating in this activity, attendees will be able to 1) Describe the impact of insomnia including the relationship between primary insomnia and daytime function; 2) Outline the pharmacology of medications used in the management of chronic insomnia; and 3) Compare and contrast the efficacy and safety of current and emerging agents used in the treatment of insomnia.

Friday, Oct. 31
7:00-9:00 a.m.
21-0 Understanding the Complexities in the Management of Insomnia and Depression: Spotlight on Current and Emerging Therapies PD
Breakfast Symposium • 1.5 credits
Marriott Hall
Supported by an educational grant from sanofi-aventis U.S. Inc.
Current antidepressants used in MDD are still not efficacious enough for many patients due to high levels of treatment resistance and bothersome side effects. “Sleep disturbances are intimately linked with the pathophysiology and the clinical symptomatology of depression. With time, most antidepressants can improve both the sleep architecture and the sleep symptoms in patients with depression, but many also have adverse effects on sleep, notably by inducing insomnia or daytime drowsiness.“ In addition, in specialized populations such as the elderly, exacerbated anticholinergic side effects have been reported with some antidepressants, rendering those agents unfeasible. There have been recent developments in novel antidepressants that demonstrate clinical efficacy in both treating depression and sleep disturbances. In order to render safe and effective care, clinicians must be aware of the complex relationship between depression and sleep, and the synergistic impact of their therapeutic interventions. By participating in the proposed educational activity, the learner will be able to:
1) Recognize the diagnostic challenges in depression and consequences of inadequate treatment (failure to achieve remission, etc); 2) Understand barriers in the management of depression including tolerability and compliance issues with current therapies; 3) Explore the relationship between insomnia and depression and how their presence impacts the outcomes of patients; and 4) Understand the efficacy and safety of current therapies and novel compounds in clinical development for the treatment of insomnia and depression.

8:00-9:15 a.m.
21-1 Practice Management Series 1A: Workflow for Enhanced Productivity PI I
Room 31A
The progressive psychiatric practice wants to enhance productivity without compromising patient service. This presentation will explore ways to manage workflow, make the most of time, and improve productivity—all the while becoming more “patient-centered.” By participating in this activity, attendees will be able to: 1) Adopt a disciplined approach to time management in the medical office; 2) Evaluate simple processes to manage workflow in private psychiatric practice; and 3) Implement protocols that will allow improved productivity while enhancing psychiatric patient service.

21-2 Returning Veterans and Exposure to Depleted Uranium: An Update PD SC
Room 29A
Mental health clinicians are being increasingly challenged by patients who believe themselves to have been exposed to radiogenic materials. This session will identify common complaints both of indigenous peoples exposed to unrefined uranium and veterans of the wars in Iraq exposed to munitions laced with depleted uranium. Department of Defense publications and politicians claim there is no health risk to the use of depleted uranium or other radiogenic materials used in combat. By participating in this activity, attendees will be able to: 1) Outline intervention strategies with patients who fear radiogenic exposure; 2) Identify symptoms reported by patients who believe they are the victims of radiogenic exposure; and (3) Examine models of intervention which appear to be effective in assisting patients who fear contamination.

21-3 Neuropsychiatric Masquerades: Medical and Neurologic Disorders that
Present with Psychiatric Symptoms NP P
Room 30A
Psychiatric masquerades are medical and/or neurological conditions which present primarily with psychiatric or behavioral symptoms. The conditions included in this category range from neurological disorders (e.g. seizure disorders and MS), to infectious diseases (e.g. syphilis, herpes and HIV), to connective tissue disorders (e.g. vasculitis and SLE), to malignancies (e.g., paraneoplastic syndromes and pancreatic cancer), to metabolic disorders (e.g. Wilson’s disease and prophyria), to various toxins and substances our patients may be exposed to. In this lecture, we will discuss the presentation and symptoms of the most common masquerades, focusing on pearls for timely diagnosis, and discuss potential management and treatment strategies. By participating in this activity, attendees will be able to: 1) Recognize the most common infectious disorders presenting with psychiatric symptoms; 2) Explain the incidence, epidemiology and clinical features of the most common neuropsychiatric disorders masquerading as psychiatric illness; 3) Recommend the research-based, effective treatment options for these conditions.

9:30-10:45 a.m.
22-0 Essential Elements in the Diagnosis and Treatment of Adult ADHD: Pathways to
Optimized Care PD PT
Room 33
Supported by an educational grant from Eli Lilly and Company.
Evidence shows that physicians still need to understand many of the complexities in the differential diagnosis of adult ADHD. Issues such as diagnostic challenges in relation to comorbid conditions and decreased functioning and quality of life implications, as well as current strategies and treatment options for the diagnosis and management of adults with ADHD are crucial. By participating in this activity, attendees will be able to: 1) Identify confounders that complicate the diagnosis of adult attention-deficit/hyperactivity disorder; 2) Understand the complexities in the diagnosis of adult ADHD; and 3) Evaluate the efficacy and safety of nonpharmacologic and pharmacologic therapeutic options for the treatment of adult ADHD.

22-1 Practice Management Series 1B: Marketing in Private Practice: Smart Tips Inside and Outside the Psychiatric Office PI
Room 31A
Marketing isn’t just about advertising, and advertising isn’t just about a full page in the phone book or 30 seconds on the radio. This presentation will help private practice psychiatrists fit the concept of marketing into their ideal of patient care. How-tos for both internal and external strategies, including staffing and training, are designed for real-world implementation and practice growth. By participating in this activity, attendees will be able to: 1) Develop effective strategies for increasing community recognition of a private psychiatric practice; 2) Enhance relationships with colleagues and other resources to ensure strong referral streams; and 3) Integrate staffing considerations into marketing decisions for improved patient service.

22-2 Pharmacotherapy of Dual-Diagnosis Patients AP RX P RX
Room 29A
The prevalence of coexisting substance misuse and psychiatric disorder (dual diagnosis) has increased over the past decade, and indications are that it will continue to rise. By participating in this activity, the attendees will be able to: 1) Describe the relative risk of comorbid substance abuse with other psychiatric syndromes; 2) Identify the available pharmacological agents for treatment of dual-diagnosis patients and medication treatment for substance dependence disorders; and 3) Discuss the difficulties relating to the treatment and the harm reduction model versus the abstinence model for dual-diagnosis patients.

22-3 Risk Management: What Is It? PI
Room 28C

12-1 Globesity: Crisis, Prospects and New TreatmentsAP PD RX AP PD RX
Room 29A

16-3 Systems Neuropsychiatry, Part 1: The Decade of the Mind NP
Room 29C

Ten prominent neuroscientists, one of them a psychiatrist, proposed in a Fall 2007 letter in Science magazine that the years 2010-2020 be devoted to a paradigm-shifting, major national research initiative: “The Decade of the Mind.” Others have asked for a coordinated international effort. Beginning with the stunning assertion that “A deep scientific understanding of how the mind perceives, thinks, and acts is within our grasp,” the Science proposal spans disparate fields such as cognitive science, medicine, neuroscience, psychology, mathematics, engineering, and computer science, with additional important insights from systems biology, cultural anthropology, social science, robotics and automation technology. For psychiatry, the implications are vast and hardly tapped, and they will be introduced in this two part seminar. Part 1 will focus upon the foundational base that cognitive neuropsychiatry affords clinical practice in the upcoming “Decade of the Mind.” By participating in this activity, attendees will be able to: 1) Describe the proposed 2010 – 2020 “Decade of the Mind,” a decade that will radically transform the way in which we promote mental health and understand and treat psychiatric disorders; 2) Identify the four pivotal, intertwined domains to be focused upon in the undertaking (healing and protecting, understanding, enriching and modeling the mind); and 3) Incorporate this knowledge into daily practice.

2008 Psychiatric Congress
1:15-3:15 p.m.
16-4 Young Clinicians Forum PI
2.0 Credits
Room 28E
I’m a doctor – now what do I do? Medical schools provide quality education, but do not offer real life practical information on the many scenarios facing young clinicians today. This interactive roundtable discussion offers the opportunity to gain insight from seasoned professionals on a variety of pertinent issues. By participating in this activity, attendees will 1) Demonstrate a deeper understanding of the business and practice aspects of medicine through sharing and networking with peers; 2) Discuss and explore practice issues affecting young clinicians; and 3) Discover how to equip themselves to respond effectively and prepare for the future as health care professionals.

3:45-6:45 p.m.
Exhibit Hall

22-3 Risk Management: What Is It? PI
Room 28C
This course will describe the field of risk management, how it developed, and how it relates to psychiatry. Included is a definition of terms. There will be a special emphasis on the area of medication errors; how they are defined, and how they can be prevented. By participating in this activity, attendees will be able to: 1) Define the scope of the field of risk management;
2) Enumerate the primary causes of medication errors; 3) Implement strategies to prevent medication errors.

22-4 The Treatment of Metabolic Syndrome in Patients with Schizophrenia and
Bipolar Disorder
Room 30C
Metabolic syndrome is more prevalent (range 30-60%) in schizophrenia and bipolar disorder patients treated with atypical antipsychotics than in the general population. The condition reflects obesity, insulin resistance and dyslipidemia and leads to higher rates of coronary heart disease and type 2 diabetes. The course will describe a) the features of metabolic syndrome as a multifactorial risk for coronary heart disease and type 2 diabetes; b) the clinical epidemiology of metabolic syndrome in patients treated with atypical antipsychotics; c) the differences in metabolic liability of the six FDA-approved atypical antipsychotics; d) the lifestyle therapeutic changes recommended for patients with metabolic syndrome; and e) the pharmacologic treatment of metabolic syndrome in psychiatric patients. By participating in this session, attendees will be able to: 1) Demonstrate increased knowledge about metabolic syndrome and its associated pathology; 2) Critically evaluate the reasons for differences in metabolic liability of the
FDA-approved atypical antipsychotics; and 3) Understand the familiarity with current guidelines for the nonpharmacologic and pharmacologic management of metabolic syndrome.

23-1 Happiness: New Insights from Social Psychology and Neuroscience NP SC C
Room 29C
Is it better conceptualized as a state, a trait, or a culture bound construct? Are there predictable and universal causes of human happiness? To what degree is one’s degree of happiness modifiable by any life event or intervention? In this session participants will get an introduction to the science of subjective well being. The session will provide an overview of the history, epidemiology, social psychology and neurobiology of happiness. By participating in this activity, attendees will be able to: 1) Explain the major biological and psychological factors associated with lasting happiness; 2) Identify the genetics, neuroimaging correlates, and typical life trajectories of happiness; and 3) List the six life interventions that appear most promising to increase lasting happiness.

23-2 Alcohol Withdrawal Syndromes: Pathophysiology and Management AP
Room 30A
Alcohol abuse is the most serious drug abuse problem in the U.S. A substantial percentage of patients presenting for treatment have alcohol related medical/neurological/psychiatric problems, many of which are associated to the presence of withdrawal syndromes. About 10% of hospitalized patients develop delirium tremens, which carries a mortality rate up to 15% when inappropriately treated. Each phase of alcohol withdrawal has its own rhythm which, if not understood, may lead to treatment errors and potentially devastating sequelae. In this lecture we will discuss the pathophysiological changes caused by alcohol dependence leading to tolerance
and the development of withdrawal syndrome; review the literature regarding diagnosis and management; review the available tools to monitor alcohol withdrawal progression and treatment effectiveness; and discuss recent studies discussing treatment management and effectiveness of various available agents. By participating in this activity, attendees will be able to: 1) Analyze the pathophysiological processes leading to the development of alcohol withdrawal syndromes;
2) Summarize the kinetics, pharmacology and side effect profile of current treatment choic